Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Regeneron Pharmaceuticals, Inc. (REGN:NASDAQ), powered by AI.
Regeneron Pharmaceuticals, Inc. is currently trading at $614.73. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Regeneron Pharmaceuticals, Inc. on Alpha Lenz.
Regeneron Pharmaceuticals, Inc.'s P/E ratio is 14.3.
“Regeneron Pharmaceuticals, Inc. trades at a P/E of 14.3 (undervalued) with solid ROE of 14.9%. Operating margin of 25.8% indicates strong profitability.”
Ask for details →Regeneron Pharmaceuticals, Inc. is a biotechnology company focused on the discovery, development, manufacturing, and commercialization of innovative medicines that address serious medical conditions. The company is recognized for its robust research platforms, particularly in the fields of immunology, oncology, and rare diseases. By leveraging advanced genetic and molecular technologies, Regeneron develops therapies targeting a broad spectrum of diseases worldwide, including ophthalmic, cardiovascular, and infectious conditions. Its portfolio includes several blockbuster biologic drugs, further underscoring its scientific leadership in monoclonal antibodies and gene therapy. Regeneron plays a pivotal role in the global healthcare sector, providing treatments that improve patient outcomes and collaborating with external partners to advance new therapeutic options. The company’s strong financial performance, with substantial revenues and consistent profitability, highlights its significant presence and influence within the biotech industry, driving both medical innovation and market growth.
“Regeneron Pharmaceuticals, Inc. trades at a P/E of 14.3 (undervalued) with solid ROE of 14.9%. Operating margin of 25.8% indicates strong profitability.”
Ask for details →Regeneron Pharmaceuticals, Inc. (ticker: REGN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 15,182 employees. Market cap is $64.3B.
The current price is $614.73 with a P/E ratio of 14.27x and P/B of 2.06x.
ROE is 14.87% and operating margin is 25.81%. Annual revenue is $14.3B.